Critical Care Medicine Doctors in Everett, WA Accepting Medicare

12 Critical Care Medicine doctors found. Showing 1 - 12

Dr. Seth Hartung, Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 12728 19th Ave Se, Suite 200, Everett, WA 98208 Phone: 425-252-1116    Fax: 425-252-1118

Thiago Antonio Jabuonski, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 12728 19th Ave Se Ste 200, Everett, WA 98208 Phone: 425-252-1116    Fax: 425-252-1118

Dr. Phillip Kenneth Gregoire, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 12728 19th Ave Se Ste 300, Everett, WA 98208 Phone: 425-791-3084

Anita E Tsen, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 12728 19th Ave. Se, Suite 200, Everett, WA 98208 Phone: 425-252-1116    Fax: 425-252-1118

Tomasz M Ziedalski, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 12728 19th Ave. Se, Suite 200, Everett, WA 98208 Phone: 425-252-1116    Fax: 425-252-1118

David A Russian, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 12728 19th Ave. Se, Suite 200, Everett, WA 98208 Phone: 425-252-1116    Fax: 425-252-1118

Sarmad Aflatooni, MD Internal Medicine - Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 1330 Colby Ave, Everett, WA 98201 Phone: 425-261-2000

John C Vandree, MD Internal Medicine - Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 1330 Rockefeller Ave, Suite 340, Everett, WA 98201 Phone: 425-252-1116

Tara E Nysoe, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1331 Colby Ave, Everett, WA 98201 Phone: 425-261-2000

Sridar Chalaka, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 3901 Hoyt Ave, Everett, WA 98201 Phone: 425-339-5410    Fax: 425-257-1433

Dr. Claude We Zeifman, MD FCCP Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 505 Waverly Ave, Everett, WA 98201 Phone: 914-924-1207

Julie Wood-mcclure, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 12728 19th Ave. Se, Suite 200, Everett, WA 98208 Phone: 425-252-1116    Fax: 425-252-1118

News Archive

Oncolytics Biotech's REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Alexza Pharmaceuticals, Inc. today announced interim results of its Phase 2a study of AZ-002 (Staccato alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study.

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.

Quick adoption of new diagnostic tests could help NHS to save nearly £7 billion

Research commissioned by Innovate UK and the British In Vitro Diagnostics Association reveals that the NHS could save over £6.9 billion in five years through quick adoption of new diagnostic tests as they come onto the market. In turn, these savings could help tackle the annual NHS shortfall, widely expected to reach £20 billion by 2022.

Read more Medical News

› Verified 3 days ago